Decreased muscarinic receptor binding in subjects with schizophrenia: A study of the human hippocampal formation

被引:190
作者
Crook, JM
Tomaskovic-Crook, E
Copolov, DL
Dean, B
机构
[1] Mental Hlth Res Inst, Div Mol Schizophrenia, Rebecca L Cooper Res Labs, Parkville, Vic, Australia
[2] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia
[3] Univ Melbourne, Royal Melbourne Hosp, Dept Psychiat, Parkville, Vic 3052, Australia
基金
英国医学研究理事会;
关键词
schizophrenia; muscarinic receptors; human hippocampus; H-3]pirenzepine;
D O I
10.1016/S0006-3223(00)00918-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Acetylcholine is important to hippocampal function, including the processes of learning and memory. Patients with schizophrenia show impaired learning and memory and hippocampal dysfunction. Thus, acetylcholinergic systems may be primarily or secondarily disrupted in the hippocampal formation of schizophrenic patients, The present study tested the hypothesis that [H-3]pirenzepine-labeled muscarinic cholinergic receptor levels are altered in the hippocampal formation of patients with schizophrenia, Methods: We have used quantitative autoradiography to measure [H-3]pirenzepine binding to M-1 and M-4 receptors in the hippocampal formation from 15 schizophrenic and IS nonschizophrenic subjects. Results: The mean density of [H-3]pirenzepine binding was reduced in all regions studied including the dentate gyrus, subdivisions of Ammon's Horn (CA1-CA4), subiculum, and the parahippocampal gyrus, of the schizophrenic cohort. Moreover, unlike controls, there was no significant variation between the mean levels of [H-3]pirenzepine binding across the subregions of the hippocampal formation from schizophrenic subjects, Conclusions: These findings provide support for a possible involvement of the muscarinic cholinergic system in the pathology and/or treatment of schizophrenia. (C) 2000 Society of Biological Psychiatry.
引用
收藏
页码:381 / 388
页数:8
相关论文
共 43 条
[1]  
[Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th
[2]  
BOLDEN C, 1992, J PHARMACOL EXP THER, V260, P576
[3]   CLOZAPINE IS A POTENT AND SELECTIVE MUSCARINIC ANTAGONIST AT THE 5 CLONED HUMAN MUSCARINIC ACETYLCHOLINE-RECEPTORS EXPRESSED IN CHO-K1 CELLS [J].
BOLDEN, C ;
CUSACK, B ;
RICHELSON, E .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 192 (01) :205-206
[4]   Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1,-adrenergic receptors in vitro [J].
Bymaster, FP ;
Nelson, DL ;
DeLapp, NW ;
Falcone, JF ;
Eckols, K ;
Truex, LL ;
Foreman, MM ;
Lucaites, VL ;
Calligaro, DO .
SCHIZOPHRENIA RESEARCH, 1999, 37 (01) :107-122
[5]  
DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474
[6]  
Dean B, 1996, BEHAV BRAIN RES, V73, P169
[7]  
DOODS HN, 1987, J PHARMACOL EXP THER, V242, P257
[8]  
Duvernoy H.M., 1991, HUMAN BRAIN SURFACE
[9]   Increased hippocampal acetylcholine release during a working memory task [J].
Fadda, F ;
Melis, F ;
Stancampiano, R .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 307 (02) :R1-R2
[10]   DIFFERENTIAL ALTERATIONS IN MUSCARINIC RECEPTOR SUBTYPES IN ALZHEIMERS-DISEASE - IMPLICATIONS FOR CHOLINERGIC-BASED THERAPIES [J].
FLYNN, DD ;
FERRARIDILEO, G ;
LEVEY, AI ;
MASH, DC .
LIFE SCIENCES, 1995, 56 (11-12) :869-876